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ABSTRACT 
 
Jason E Lambert DDS 
 
Effect of Minor SNPs on Enzymatic Activity Regulated by Common Human Haplotypes of 
the Catechol-O-methyltransferase Gene 
(Under the direction of Dr. Luda Diatchenko, Dr. Linda Levin, Dr. William Maixner,  
Dr. Andrea Nackley Neely, Dr. Timothy Wright) 
 
Three common haplotypes of the human catechol-O-methyltransferase (COMT) 
gene are associated with experimental pain sensitivity. Based on subjects’ pain 
responsiveness, haplotypes were designated as low (LPS), average (APS), or high 
(HPS) pain sensitive; APS and HPS haplotypes exhibit lower COMT enzymatic 
activity. Minor frequency SNPs naturally occur within the APS and HPS haplotypes, 
but their functional impact is unknown. We hypothesized that these minor SNPs, one 
occurring in the APS construct (G/A, rs769224) and three in the HPS construct (G/T, 
rs6267; G/A, rs740602; C/T, rs8192488), may compensate for the observed 
reductions in enzymatic activity. Testing was carried out via transient transfection of 
rat adrenal (PC-12) cells with each of the four constructs. No difference exists 
between the haplotype mutants and their respective parent haplotype for RNA 
abundance, protein expression, or enzymatic activity (P > 0.05). Additionally, the 
minor allele of SNP re6267 is a likely marker of the HPS haplotype. 
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INTRODUCTION 
 
 
PAIN AS A PROTECTIVE MECHANISM 
 
 Pain is defined as “an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage, or described in terms of such damage” (Merskey, 1994). 
Pain perception occurs before tissue damage begins, thus serving as a protective mechanism. 
It helps the individual avoid dangerous situations by moving away from noxious stimuli, so 
as to not experience the unpleasant sensation. For example, classic experiments have shown 
that the threshold for thermal pain corresponds to the temperature at which tissue damage 
begins (Hardy et al., 1952).  
 Pain also promotes the healing process through prompting the individual to recognize 
the injury and protect the area from further damage, thereby minimizing the experience of 
more pain. Congenital insensitivity to pain is a medical condition in which persons are born 
without the ability to perceive pain (Nagasako et al., 2003). This condition gives compelling 
evidence that pain is critical for the protection and survival of an individual. During 
childhood these individuals tend to sustain severe wounds, some mortal, because the 
protective mechanism of pain is absent. Even into adulthood pain-insensitive individuals 
injure their soft tissue and joints by failing to shift their weight while sitting, standing, or 
sleeping. Furthermore, their injuries tend to heal slower because they do not take measures to 
guard these areas. 
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 Pain has sensory-discriminative and affective-motivational components that are 
processed in multiple distinct cortical regions of the brain (Treede et al., 1999). The sensory-
discriminative component can be considered a sensory modality similar to taste or vision, 
giving information such as stimulus location, intensity and quality discrimination. The 
affective-motivational portion accounts for the emotional reaction to pain, which is 
subjective and depends upon arousal level and behavior programming. The typical 
unpleasantness or ‘suffering from pain’ provides motivation to remove oneself from the 
stimulus. Above all else, the overriding evolutionary reason for the existence of pain is to aid 
in the survival of the individual. 
IDIOPATHIC PAIN DISORDERS 
 Pain has a definite protective role that benefits the individual, but in conditions where 
chronic pain persists in the absence of a noxious stimulus, pain becomes the disease itself. 
Complex medical conditions referred to as idiopathic pain disorders (IPDs) share a common 
trait wherein the patient reports a pain level that is greater than would be expected by a 
physical examination (Diatchenko et al., 2006c). Such examples of IPDs include 
temporomandibular joint disorder (TMJD), fibromyalgia syndrome, irritable bowel 
syndrome, chronic headaches, chronic pelvic pain, chronic tinnitus, and whiplash-associated 
disorders. 
 It has been shown that acute pain can be attenuated by experimentally applying a 
submaximal level  noxious stimulus at a distant site. However,  pain arising from an IPD 
cannot be consistently reduced in this manner, which highlights a key distinction between 
acute and chronic pain (Maixner et al., 1995; Sigurdsson and Maixner, 1994). It also strongly 
suggests that there is a different underlying biologic mechanism between acute and chronic 
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pain. Currently, there is an incomplete understanding of the pathophysiology of the nature of 
chronic pain conditions. 
 All IPD patients do not exhibit the same pattern of altered function in pain 
amplification or psychological distress. It is therefore plausible that the phenotypes 
associated with IPDs are the result of multiple genes interacting with each other under the 
influence of the environment. The subclassification of IPDs based on the specific network of 
genetic variations in each individual will allow better and more informed individual-based 
treatments. 
Mechanisms Contributing to IPDs 
 Chronic pain results from the dysfunction or dysregulation of normal pain 
mechanisms and pathways. Melzack (Melzack, 1999) proposed a mechanism by which pain 
persists in the absence of tissue damage. The theory states that neural pathways link multiple 
regions of the brain responsible for integrating inputs and creating a pattern-generating 
process that is distinct from the environment and perception of pain. These activity patterns 
are determined genetically and modified by sensory and pathologic inputs, activity from the 
endocrine, immune, and autonomic systems, medullary descending activity, CNS plasticity, 
attention, and cognitive and emotional states. Therefore, any factor within this matrix can 
bring about a change in pain transmission or modulation, which will have consequences in 
pain perception and behavior. It was proposed that certain alterations of the pathways within 
the matrix have the ability to bring about the onset of chronic pain. 
 Building upon Melzack’s theory, recent evidence has led researchers to consider 
biological and psychosocial factors to explain abnormal pain experiences (Bradley and 
McKendree-Smith, 2002). Prospective and cross-sectional studies have reported an increased 
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risk of developing an IPD in individuals with enhanced pain amplification (Sarlani and 
Greenspan, 2003; Verne and Price, 2002; Von Korff et al., 1988) and persons with higher 
levels of psychological distress (McBeth et al., 2001). Diatchenko and colleagues 
(Diatchenko et al., 2006c) suggested that these two factors represent distinct primary 
pathways through which IPDs may develop. Exposure to environmental elements may 
initiate or further accentuate disturbances in pain perception or psychosocial disposition, 
which is ultimately determined at the genetic level. When an individual has both enhanced 
pain sensitivity and higher levels of distress, then the vulnerability to developing an IPD is 
synergistically compounded. 
Pain Amplification as a Determinant of IPD Onset and Persistence 
 The most consistent predictor of developing a chronic pain disorder is the presence of 
another chronic pain condition(Von Korff et al., 1988); thus, factors that influence pain 
sensitivity may contribute to the development of a variety of chronic pain conditions. 
 Primary hyperalgesia, as described by Hardy (Hardy et al., 1950), is the lowering of 
the pain threshold at the site of injury. (Coderre et al., 1993). Under certain conditions, this 
peripheral sensitization may give rise to hyperexcitability and increased receptive fields of 
wide dynamic range neurons (Dougherty and Lenz, 1994) or cause dynamic changes in the 
supporting glial cells of the central nervous system (CNS ) (Watkins and Maier, 1999; 
Watkins et al., 2003), leading to central sensitization. Central sensitization is a collective 
term that encompasses plastic changes within the CNS (Treede et al., 1992), and may play a 
crucial role in the development of chronic pain. Secondary hyperalgesia, the lowering of the 
pain threshold in undamaged surrounding tissue, as well as allodynia, an exaggerated 
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response to otherwise non-noxious stimuli, may result from prolonged exposure to any 
number of inflammatory mediators (Levine and Taiwo, 1994). 
 Pain amplification can also result from the dysregulation within any portion of the 
afferent neural pathway. Normally, the descending neural inhibitory control releases 
endogenous opioids to attenuate nociceptive signals before reaching the cortical level of 
brain (Gebhart, 2004) . When functioning abnormally, however, the descending neural 
inhibitory control can be switched off , which would act to increase pain sensitivity (Vanegas 
and Schaible, 2004). 
 Pain regulatory systems within the CNS may be affected by the carotid sinus 
baroreceptors activation (Dworkin et al., 1994) as exemplified in the relationship between 
resting arterial blood pressure and pain threshold. Maixner  (Maixner et al., 1997) found an 
association between blood pressure and pain threshold in healthy, pain-free subjects, but a 
similar relationship was not present in patients with an IPD.  This result is consistent with the 
view that IPDs are associated with an impaired pain regulatory system. 
 It has also been reported that the presence of widespread, as opposed to localized, 
pain in individuals with an IPD is an indicator for a poorer treatment response, and 
consequently  morbidity of longer duration (Raphael and Marbach, 2001). Taken as a whole, 
individuals with a high state of pain amplification have a greater propensity to develop an 
IPD. 
Psychological Distress as a Determinant of IPD Onset and Persistence 
 Specific psychosocial traits have been associated with IPD onset and persistence. 
Patients with an IPD have significantly higher levels of depression, anxiety, and perceived 
stress relative to pain-free individuals (Beaton et al., 1991; Vassend et al., 1995), and are 
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more likely to seek medical care (Kersh et al., 2001). Somatization, the general tendency to 
perceive and endorse physical symptoms, is another major psychosocial risk factor for 
developing chronic widespread pain in IPD patients (McBeth et al., 2001; Wilson et al., 
1994). Widespread pain, as discussed in the previous section, has been implicated as an 
indicator for poorer treatment prognosis in IPD patients. It was not only associated with 
poorer treatment outcomes in a five-year study (Ohrbach and Dworkin, 1998), but patients 
actually had increased pain following treatment (McCreary et al., 1992). Somatization was 
also found to be predictive for pain progressing from an acute state to a chronic state 
(Garofalo et al., 1998). Higher levels of psychological distress manifest through the complex 
interaction of genetic and environmental factors to influence the vulnerability of an 
individual to developing an IPD. Among these, depression, anxiety, stress and somatization 
are the most recognized traits. 
Genetic and Environmental Contribution to Pain Amplification and 
Psychosocial Distress 
 Pain amplification and psychological distress are complex traits modulated by 
complex physiologic pathways. Although the intricacies and interactions of these pathways 
have not been fully elucidated, they are known to be mediated by genetic and environmental 
factors. Genetic factors in this context relate specifically to genes, the localized units of an 
individual’s entire DNA structure that code for proteins. In 2003 the Human Genome Project 
completed sequencing the approximately three billon base pairs of the human genome, which 
contain an estimated 20,000 to 25,000 genes (Finishing the euchromatic sequence of the 
human genome, 2004). The resulting data are invaluable as a broad reference, but focused 
research is necessary to decipher the relationship between genotype and phenotype. The 
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individual variability in gene expression and resulting biochemical interactions suggests a 
myriad of possible interactions at multiple levels of gene regulation and protein activity. The 
current theory states that an individual is at risk for developing an IPD when environmental 
events cause injury or stress of a particular level to an individual with a predisposed 
phenotype (Diatchenko et al., 2006c). 
 Genetics. The degree of genetic influence on nociception and analgesic sensitivity 
is unknown, but has been estimated in mice to fall within a range of 28 to 76% (Mogil, 
1999). Singe-gene pain disorders that follow Mendelian inheritance patterns exist but are 
extremely rare. The best known example is the group of  single genetic mutations of the 
NTRK1 gene that result in congenial insensitivity to pain (Mogil and Max, 2004), discussed 
previously. The NTRK1 gene codes for a receptor for nerve growth factor (NGF), which 
induces neuronal growth and promotes survival of embryonic sensory and sympathetic 
neurons. 
 However, most pain disorders are multifactorial. Given the complex nature of the IPD 
phenotypes, a single mutation is neither sufficient nor necessary for developing the IPD 
phenotype. Instead, these genetic factors are highly prevalent polymorphic genes. It has been 
reported that polymophisms of specific genes involved in pain pathways can be associated 
with behavior-level variability (Mogil et al., 2003; Zubieta et al., 2003). 
 In terms of psychosocial traits, it is established that genetic factors are significantly 
involved. Specifically, there is an estimated 40% to 70% heritability of unipolar depression 
(Lesch, 2004), while evidence from twin studies suggest that 30% to 50% of risk of 
developing any anxiety disorder can be attributable to genetic factors (Gordon and Hen, 
2004).  
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 A list of genes previously associated with both enhanced pain sensitivity and high 
levels of  psychosocial distress, while not intended to be exhaustive, is used here to 
demonstrate the diverse genetic field that contributes to pain perception: catechol-O-
methyltransferase (COMT) (Diatchenko et al., 2005), adrenergic receptor β2 (ADRB2) 
(Diatchenko et al., 2006a), serotonin transporter (Gordon and Hen, 2004) , D2 dopamine 
receptor (Lawford et al., 2003), and interleukins 1 α and β (Yu et al., 2003). 
 A prospective-longitudinal study by  Caspi and colleagues (Caspi et al., 2003) was 
the first to report that an individual's response to environmental events is controlled by 
genetics. A specific alteration present in the serotonin transporter gene was found to 
moderate the influence of stressful life events on depression, leading to a higher prevalence 
of depression and suicide. 
 Environment. The environment has a substantial influence on pain onset and 
maintenance. Injuries can occur anywhere, but particular surroundings increase susceptibility 
as evident in comparing a factory floor to an office workplace. An employee’s occupational 
environment has both a biomechanical and psychosocial influences on pain (van der Windt et 
al., 2000). A few examples include musculoskeletal injury secondary to high-force physical 
movements or low-force repetitive movements (Hagberg, 1983), poor ergonomics such as 
posture and workspace design (Ayoub, 1990), as well as stress arising from high job 
demands (Burton, 1997; Hviid Andersen et al., 2002). Sociodemographic factors such as 
employment status, city population, and number of children living at home have also been 
correlated to levels of pain (Ektor-Andersen et al., 1993). Clearly, the environment, which 
has physical and psychosocial impacts upon individuals, must be considered as a main factor 
in the development and persistence of pain. 
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TEMPOROMANDIBULAR JOINT DISORDER 
 Painful temporomandibular joint disorder (TMJD) is a common IPD and the most 
common chronic orofacial pain condition (Dworkin and LeResche, 1992). Myogenous TMJD 
is the most common form and is associated with persistent pain in the temporomandibular 
joint, the area around the ear, and the muscles of the head and neck that can lead to impaired 
oral function (Von Korff et al., 1993). The estimated prevalence within the United States is 
approximately 12% of the adult population, with a female-to-male ratio of 8:1. Females of 
reproductive age represent the largest portion of the afflicted (Dworkin et al., 1990). The 
estimated health costs of TMJD is one billion dollars per year. TMJD is a complex disorder 
that is induced and influenced by environmental events and multiple genetic variants. Given 
the nature of this complex disorder, twin and familial studies would require many thousands 
of cases in order to determine the heritability (Risch, 2000). To date, studies designed to 
identify and characterize polymorphisms in specific genes that are associated with pain 
processing and risk of myogenous TMJD development have been successfully employed 
(Diatchenko et al., 2005; Diatchenko et al., 2006a; Herken et al., 2001). TMJD onset and 
persistence is associated with a heightened state of pain amplification and psychosocial traits. 
Pain Amplification in TMJD Patients 
 Early studies found that orofacial pain patients often suffer from other chronic pain 
conditions such as back pain and migraine headaches (Berry, 1969; Gold et al., 1975). 
Differences in pain threshold to noxious stimuli between patients with TMJD and healthy 
control subjects was first reported over three decades ago (Molin et al., 1973a). In a similar 
study of pressure threshold, Malow (Malow et al., 1980) made the same conclusion. Reid 
(Reid et al., 1994) measured pain-pressure thresholds of TMJD patients. The results show 
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that sufferers have a lower pain threshold to pressure on both the more-painful and less-
painful sides of their faces. This was confirmed by Maixner (Maixner et al., 1998). It was 
found that TMJD patients have reduced experimentally-induced pressure pain thresholds at 
both painful and pain-free sites across the body as compared to normal subjects. It has further 
been reported that TMJD patients also have diminished pain tolerance to thermal and 
ischemic noxious stimuli (Maixner et al., 1995; Maixner et al., 1998). The conclusions 
suggest that TMJD arises due to  imbalances in the pain transmitting and regulatory 
pathways. Kashima and colleagues (Kashima et al., 1999) tested the ischemic pain threshold 
and tolerance of female TMJD patients and healthy control subjects. They too concluded that 
individuals with TMJD  have increased pain sensitivity at remote sites, and suggested that 
endogenous opioid systems are impaired in TMJD patients. 
 An additional finding of Maixner (Maixner et al., 1998) was that TMJD patients were 
more sensitive to repeated applications of heat pulses applied to various skin sites than 
control subjects, but that TMJD patients exhibited no difference in their ability to 
discriminate small increments of noxious heat. The test whereby perceived thermal pain 
intensity is measured when a constant-intensity noxious stimulus is delivered repeatedly is a 
test of temporal summation of pain. This process of pain is mediated by the CNS, with a  
resulting increase in excitability of the CNS nociceptors (Price et al., 1977). Increased local 
and global pain sensitivity as well as increased sensitivity to temporal summation of pain in 
TMJD patients suggests that TMJD pain has a centrally mediated component. 
Psychosocial Distress in TMJD Patients 
 Psychosocial traits are strongly correlated to the development of TMJD and the 
success of treatment. Molin (Molin et al., 1973b) and later Schwartz (Schwartz et al., 1979) 
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were the first to  report the personality profiles of orofacial pain patients. Each noted that 
patients had high levels of anxiety and stress. Since then, multiple studies have confirmed 
these findings as TMJD patients score significantly higher on tests for depression (Bassett et 
al., 1990), anxiety (Carlson et al., 1993; Goss et al., 1990), somatization (Wilson et al., 
1994), anger (Herken et al., 2001), and perceived stress (Beaton et al., 1991) as compared to 
control subjects. In addition to anxiety, Vassend (Vassend et al., 1995) reported that general 
somatic complaints are also key predictors for future TMJD pain, response to treatment, and 
persistence. TMJD patients with somatization are less likely to experience relief following 
treatment (McCreary et al., 1992)  and more likely to have widespread painful areas (Wilson 
et al., 1994). A five-year TMJD outcome study reported that clinical signs were poor 
predictors of pain while somatization was closely related to pain improvement. Only those 
patients who exhibited significant psychosocial improvement were represented in the group 
with the greatest relief of TMJD facial pain (Ohrbach and Dworkin, 1998). Similarly, TMJD 
patients with an adaptive coping profile improved significantly relative to those with a 
dysfunctional coping profile (Epker and Gatchel, 2000).  
Genetic Variants of COMT Associated with Pain Perception and TMJD 
 TMJD has been associated with variants of genes previously implicated in 
modulating pain perception. Of these, catechol-O-methyltransferase (COMT), a key enzyme 
that metabolizes epinephrine, norepinephrine, and other catecholamines, is the primary focus 
here. Genetic variants of  COMT affect the normal mechanism by which epinephrine is 
physiologically modulated.  
 Experimental animal models of rheumatoid arthritis support that adrenergic systems, 
including those specifically related to epinephrine and beta-adrenergic receptors (βARs), 
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influence pain perception (Levine et al., 1988). In fact, persistent pain states are possible to 
induce experimentally by elevating levels of epinephrine, whereby the increased 
bioavailability of epinephrine stimulates βARs, leading to the increased pain (Coderre et al., 
1990). Furthermore, epinephrine sensitizes bradykinin receptors, which have been implicated 
in contributing to IPDs (Khasar et al., 2003).  
 A Role for COMT in the Modulating Pain. The first evidence 
suggesting that altered catecholamine metabolism was associated with a painful facial 
condition similar to TMJD was reported by Marbach and Levitt (Marbach and Levitt, 1976). 
This study showed that pain patients had higher urinary levels of catecholamine metabolites 
with concomitant lower enzymatic activity of COMT. Given the significant evidence 
inversely relating COMT activity to pain sensitivity (Diatchenko et al., 2005), a series of 
experiments by Nackley and colleagues (Nackley et al., 2006b) sought to elucidate the 
method by which such elevated catecholamine levels lead to heightened response to noxious 
stimuli. In order to identify this pathway, rats were injected with COMT inhibitor to produce 
a high levels of epinephrine and norepinephrine, which quickly leads to significant 
hyperalgesia (Diatchenko et al., 2005). Testing to mechanical and thermal stimuli confirmed 
a significant increase in sensitivity. This effect was blocked by either propranolol, a 
nonselective beta-adrenergic receptor (βAR) antagonist, or the combined use of selective β2- 
and β3-AR antagonists. Thus, through the use of an animal model designed to produce 
persistent pain states similar to those in humans suffering from TMJD or fibromyalgia, 
COMT-dependent pain sensitivity was found to be derived through β2/3-AR signaling 
pathways. It is unknown, however, whether this process occurs in the central or peripheral 
 21 
adrenergic system. Additionally, polymorphisms of β2AR have been associated with 
increased vulnerability to TMJD (Diatchenko et al., 2006a). 
 Genetic variants of COMT. Genetic variants of COMT are known to impact 
the two main pathways of IPD development in human: amplified pain experience (Rakvag et 
al., 2005; Zubieta et al., 2003) and psychosocial distress (Funke et al., 2005). It is necessary 
here to specifically discuss the broad aspect of these genetic variants in more detail along 
with their modes of impact as a basis for the next chapter. 
 Single Nucleotide Polymorphisms. Single nucleotide polymorphisms (SNPs) are 
common variations in the DNA sequence whereby one nucleotide differs between paired 
chromosomes within an individual or between members of the same species (Stephan and 
Glueck, 2002). SNPs that impact the gene expression or protein functionality are termed 
functional. These can occur in either the coding or the non-coding portion of the gene. This 
functionality may be deleterious, neutral or beneficial to the individual. 
 When SNPs are within the exons, or coding regions, of genes, they are referred to as 
either synonymous, if the amino acid sequence is unchanged, or non-synonymous, if a 
different amino acid is substituted as a result. Non-coding SNPs can also be functional 
(Kanaji et al., 1998), as they either exist in regulatory portions of the gene or in locations 
important for splicing, translocation, or transcription. Particular attention has been paid to the 
role that non-synonymous  SNPs play in altering gene function due in part to their evident 
impact at the protein level (Yampolsky et al., 2005). However, it has been shown that 
synonymous SNPs can also have as great or greater an impact on phenotypic expression 
(Diatchenko et al., 2005; Duan et al., 2003). 
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 Haplotypes. Haplotypes, which are collections of SNPs, have been shown to explain 
functional outcomes better than individual SNPs (Davidson, 2000). Determining the 
functionality of synonymous and non-coding SNPs can be difficult and often times 
confounded as linkage disequilibrium, or the likelihood of two SNPs being inherited together 
due to proximity within the DNA sequence, increases. Tactics such as analyzing groups of 
SNPs through haplotypic analysis has been successfully used to resolve such regulatory 
SNPs  (Knight, 2005). Furthermore, with direct respect to COMT, combinations of 
synonymous and nonsynonymous SNPs are known to have functional consequences that are 
different from those expected by the sum of each functional allele’s individual contribution 
to predict COMT activity (Diatchenko et al., 2005). 
 COMT haplotypes associated with TMJD onset. Recently, a 
prospective study reported that COMT haplotypes based on subjects’ pain sensitivity were 
associated with TMJD. The study followed 202 healthy females over three years and found 
that a specific COMT haplotype was associated with increased pain sensitivity and risk for 
developing TMJD (Diatchenko et al., 2005). This study is discussed in greater detail in the 
following chapter. 
CATECHOL-O-METHYLTRANSFERASE 
The COMT Gene and Protein 
 Catechol-O-methyltransferase (COMT), first categorized by Axelrod and Tomchick 
(Axelrod and Tomchick, 1958), is an enzyme involved in the metabolism of chemical 
compounds with a catechol structure. COMT is a key enzyme in the modulation of 
dopaminergic and adrenergic neurotransmission as it catalyzes the first step in the 
metabolism of catechol-containing molecules. The primary physiological substrates of 
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COMT are the catecholamines epinephrine, norepinephrine and dopamine, which are 
hormones and neurotransmitters derived from tyrosine. COMT also metabolizes 
catecholestrogens, catechol-containing flavonoids, ascorbic acid and L-dopa (Mannisto and 
Kaakkola, 1999). Degradation begins with COMT transferring a methyl group donated by S-
adenosyl methionine (SAM) to the catechol. The liver contributes the highest level of 
enzymatic activity, but COMT is found in all human tissues (Mannisto et al., 1992). 
 One gene, two proteins. A single gene (Fig. 1) found on human 
chromosome 22 codes for two protein isoforms: soluble COMT (S-COMT) and membrane-
bound COMT (MB-COMT) (Grossman et al., 1992). Two distinct promoters are responsible 
for transcribing the two proteins (Lundstrom et al., 1991). S-COMT is comprised of 221 
amino acids. MB-COMT contains an additional 50 amino acids, some of which anchor the 
molecule to the cytoplasmic face of intracellular membranes (Mannisto and Kaakkola, 1999). 
S-COMT is the dominant form expressed in the periphery; moderate to high concentrations 
are present in the liver, kidney, spleen, and adrenal gland (Tenhunen et al., 1994). MB-
COMT is the exclusive form expressed in the central nervous system (CNS), where 
substantial concentrations are present in both neurons and glia (Hong et al., 1998; Tenhunen 
et al., 1994).  
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 The kinetic properties of S-COMT and MB-COMT vary greatly and are dependent 
upon the substrate. For example, MB-COMT is found within interstitial neurons postsynaptic 
to dopaminerigic neurons, where relatively low concentrations of dopamine occur. MB-
COMT is better suited for this condition since it has higher affinity for dopamine at this 
concentration (Rivett et al., 1983). S-COMT is found mostly in glial cells outside of the CNS 
and is present in greater abundance than MB-COMT by a factor of at least 3 (Tenhunen et 
al., 1994). In the periphery, dopamine concentration is greater, which matches the enzymatic 
profile of S-COMT. The high-capacity nature of S-COMT compensates for the lower affinity 
for dopamine of S-COMT as compared to MB-COMT (Malherbe et al., 1992). 
 Differences in COMT activity have been reported among ethnic groups (Ameyaw et 
al., 2000; McLeod et al., 1998). For example, Caucasians have relatively lower COMT 
activity as compared to Orientals (Rivera-Calimlim and Reilly, 1984) and African-Americans 
(McLeod et al., 1994).  Differences also exist between genders, where females have a 20 to 
30% lower COMT activity than males (Boudikova et al., 1990).  
 COMT polymorphisms. There are over 120 SNPs in the COMT gene as 
detailed by the National Center for Biotechnology Information (NCBI) database 
5´ 3´ 
S-COMT promoter MB-COMT promoter 
Figure 1. COMT Gene Locus. COMT is located at chromosome 22 band q11.2. 
This schematic representation of COMT depicts two distinct promoters  and six 
separate exons    . The promoter further upstream is responsible for the membrane-
bound isoform of COMT. 
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(http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId=1312&chooseRs=all). Eleven SNPs 
have a minor allele frequency of at least 35%, with seven more having at least a 3% minor 
allele frequency. The most commonly researched SNP, designated rs4680, is 
nonsynonymous and occurs at codon 158 of MB-COMT.  Here a transition of guanine (G) to 
adenine (A) results in an amino acid change from valine (val) to methionine (met) (Lotta et 
al., 1995). Palmatier (Palmatier et al., 1999) reported that valine is the ancestral allele in 
humans. The study also reported the allelic frequencies of this SNP as genotyped from some 
1,300 individuals representing 30 world-wide populations. Ethnic differences were distinct, 
with individuals of European ancestry having nearly equal frequencies of the two alleles. All 
other populations had a much lower prevelance of methionine. Recent studies have 
associated the presence of the met158 substitution with variations in pain perception (Zubieta 
et al., 2003) and psychosocial traits such as anxiety (Enoch et al., 2003) and panic disorders 
(Domschke et al., 2004). 
 A nonsynonymous polymorphism Affects COMT Activity.  
The level of COMT activity was initially categorized as a trimodal distribution of low, 
intermediate and high, with a 3- to 4-fold difference existing between the low and high 
activities (Lotta et al., 1995). The marked variation in enzymatic activity was determined to 
be caused by autosomal codominant alleles (Weinshilboum and Raymond, 1977). Therefore, 
individuals could be either homozygous for low (COMTLL) or high (COMTHH) COMT 
activity or heterozygous (COMTLH). The decreased enzymatic activity of  COMTL, the low 
activity allele, was  already known to be attributed to the poor thermostability of the enzyme 
(Scanlon et al., 1979; Spielman and Weinshilboum, 1981). Researchers discovered the 
underlying genetic difference of the two COMT variants, revealing that the diminished 
thermostability of COMTL was the result of the val158met substitution in both S-COMT and 
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MB-COMT (Lachman et al., 1996b; Lotta et al., 1995). The met158 substitution is associated 
with the lower thermostability and resulting decreased enzymatic activity. 
COMT Polymorphisms Associated with Disease Phenotypes 
 COMT has been implicated in regulating dopamine and norepinephrine levels in the 
brain, which have an effect on mood and cognitive abilities (Weinberger et al., 2001) as well 
as Parkinson’s (Kunugi et al., 1997; Yoritaka et al., 1997) and Alzheimer’s (Zhu, 2002) 
diseases. Velocardiofacial syndrome (VCFS) is a genetic disorder that is associated with the 
deletion of a portion of chromosome 22q11, including the region containing the COMT gene.  
Patients inflicted with VCFS have increased prevalence of psychosis (Murphy et al., 1999) 
and schizophrenia (Lachman et al., 1996a).  
 Numerous studies have reported modest associations between the val158met 
substitution and various complex phenotypes including schizophrenia (Egan et al., 2001), 
late-onset alcoholism (Tiihonen et al., 1999), fibromalgia syndrome (Gursoy et al., 2003), 
obsessive-compulsive disorder (Karayiorgou et al., 1997), anorexia nervosa (Frisch et al., 
2001), and cognitive function (Egan et al., 2001; Gallinat et al., 2003; Winterer et al., 2006). 
However, numerous studies also exist that report no association between the met allele and 
disease phenotype: schizophrenia (Lee et al., 2005; Munafo et al., 2005) and obsessive-
compulsive disorder (Azzam and Mathews, 2003) are examples. 
 Sweet (Sweet et al., 2005) identified a significant association between Alzheimer’s 
disease with psychosis and a four-locus haplotype of COMT, which included val158met 
(rs680). Lee (Lee et al., 2005) found that the nonsynonymous SNP at codon 72 in MB-
COMT, designated rs6267, was a risk factor for schizophrenia. A lower COMT activity was 
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detected when both minor alleles at codons 72 and 158 were present as compared to the 
presence of each individually. This study is further discussed later in this chapter. 
COMT Polymorphisms Associated with Pain Sensitivity 
  Studies have found that a sustained increase in catecholamine levels has been 
associated with chronic musculoskeletal pain conditions such as fibromyalgia syndrome 
(Torpy et al., 2000) and myofascial pain condition (Evaskus and Laskin, 1972). Experimental 
trial evidence implicates catecholamines levels in modulating pain sensitivity (Bie et al., 
2003). An experimentally-induced decrease in available COMT, via an inhibitor, heightens 
pain sensitivity in rats comparable to that achieved with carrageenan (Diatchenko et al., 
2005), a well-characterized nociceptor-sensitizing chemical (Hedo et al., 1999). 
 Val158Met and Pain. Conflicting clinical data exist regarding whether the 
val158met substitution has a significant effect on pain sensitivity. Zubieta (Zubieta et al., 
2003) reported that subjects homozygous for the met158 allele had great pain responsiveness. 
In contrast, Kim (Kim et al., 2004) found that gender, ethnicity, a polymorphism in an opioid 
receptor gene, and temperament all have effects on pain sensitivity, but failed to identify the 
met158 allele as a contributing risk factor. Rakvåg (Rakvag et al., 2005) reported that cancer 
patients with the Val/Val genotype at codon 158 used more morphine as compared to the 
Val/Met and Met/Met groups. There is not a definitive relationship between pain sensitivity 
and val158met. 
 Haplotypes and pain. Diatchenko and colleagues demonstrated that three 
common haplotypes of the human COMT gene account for pain perception and the likelihood 
of developing TMJD (Diatchenko et al., 2005). Data were collected from 202 healthy 
females in a 3-year prospective study. Genomic DNA was obtained from blood samples and 
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genotyped for SNPs within the COMT gene locus. Six SNPs with at least a 40% prevalence 
of polymorphism within humans were genotyped. Linkage disequilibrium (LD) analysis 
determined three haploblocks within the COMT gene, consistent with previous LD analyses 
(Li et al., 2000; Shifman et al., 2002). Three major haplotypes, which accounted for 95.9% of 
all detected haplotypes, were formed by four SNPs: one located in the S-COMT promoter 
region (A/G; rs6269) and three in the S- and MB-COMT coding region at codons His62His 
(C/T; rs4633), Leu136Leu (C/G; rs4818), and Val158Met (A/G; rs4680). Strong LD 
associations exist between SNPs rs6269 and rs4818 (D′ = 0.94, R2 = 0.88) and SNPs rs4633 
and 4680 (D′ = 0.96, R2 = 0.91).  
Subjects homozygous for the GCGG haplotype had the lowest pain sensitivity (LPS), 
homozygous for the ATCA haplotype had average pain sensitivity (APS), and heterozygous 
for ATCA and ACCG haplotypes had the highest pain sensitivity (HPS; = ACCG haplotype). 
Each haplotype effected pain sensitivity (P<0.01) and accounted for ~11% of the variation in 
pain sensitivity. APS and HPS haplotypes were associated with high pain sensitivity and 
increased TMJD risk (Fig. 2).  
 Haplotypes and val158met differentially influence pain 
perception. Although a strong correlation between the designated haplotypes and a 
global measure of pain sensitivity exists, the val158met polymorphism alone was not 
significantly associated with the overall pain measure (p=0.18). It was hypothesized that 
val158met and COMT haplotypes affect various modalities of pain perception through the 
expression and activity of the S-COMT and MB-COMT isoforms. Subsequent data analysis 
of COMT haplotypes and diplotypes compared each subject’s sensitivity to specific pain  
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 Codon 3102102 62 136 158 
 
 Contribution to global 
 pain sensitivity, % <0.0001 2  7 2 
 
 
   
Haplotype Designation & Sequence Frequency, %  
  
 LPS: G --- C -------------- G --- Gval 36.5 
  
 APS: A --- T -------------- C --- Amet 48.7 
 
 HPS: A --- C -------------- C --- Gval 10.7 
 
Figure 2. Summary of Haplotypic Analysis 
from Diatchenko (2005). (A) MB-COMT is               
shown with coding regions  , SNPs 
contributing to haplotypes (non-synonymous 
bolded), SNP frequencies, and SNPs with 
strong LD values    ,   . The corresponding 
codon position is listed beneath each SNP. 
Percent of independent contribution to global 
pain sensitivity is listed for each SNP.  (B) 
The haplotype sequences (SNPs rs6269, 
rs4633, rs4818, rs4680) and frequency within 
the cohort of 202 healthy Caucasian females 
are detailed. (C) Higher pain responsiveness is 
associated with diplotypes comprised of the 
APS and HPS haplotypes. There were too few 
subjects with the HPS/HPS combination to 
contribute to this data.  
 
modalites: pressure, thermal, and ischemic pain and thermal temporal summation 
(Diatchenko et al., 2006b) 
 Resting nociceptive sensitivity. Thermal pain stimuli was the only stimuli 
significantly related to COMT haplotypes and diplotypes. Individuals with the APS/HPS 
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diplotype were the most responsive to painful thermal stimuli, while individuals with the 
LPS/LPS diplotype were the least responsive. There were too few HPS/HPS individuals to 
include in the analysis. Neither mechanical nor ischemic pain were found to be significantly 
related to diplotype. As previously shown, the val158met SNP rs4680 could not be used to 
explain the observed differences in resting nociceptive sensitivity. 
 Temporal integration of pain. Although the mean responses to repeated application 
of heat pulses were related to diplotypes, the rate of temporal summation was not. The rate 
was significantly associated with the val158met polymorphism. Individuals homozygous for 
met158 had steeper pain response rates as compared to val/val homozygous individuals, 
strongly suggesting that SNP rs4680 accounts for variability in temporal summation of 
thermal pain. Therefore, the val158met allele can explain the differences in pain sensitivity 
experienced between individuals with the APS versus LPS haplotype. This conclusion is 
supported by Zubieta (Zubieta et al., 2003), who reported an association between prolonged 
experimentally-induced muscle pain sensitivity and the met158 polymorphism. COMT 
haplotypes were not associated with the CNS-mediated pain process of temporal summation. 
Mechanisms of COMT Haplotypes   
 mRNA secondary structures. Interestingly, both LPS and HPS 
haplotypes code for identical amino acid sequences, yet are associated with the greatest 
difference in pain responsiveness. Since both LPS and HPS haplotypes code for the more 
thermostable val variant, clearly SNP  rs4680 cannot explain the observed variation in pain 
sensitivity among the study subjects. 
 Since neither SNP rs6269 nor rs4633 located in the promoter region of S-COMT 
contributed significantly to pain sensitivity, it was considered unlikely that mRNA 
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expression would explain the difference in enzymatic activity. Quantitative real-time 
polymerase chain reaction (QRT-PCR) measurements detected no difference in COMT 
mRNA abundance among the three haplotypes. Therefore, haplotype-specific differences 
were dependent upon only the three coding-region SNPs [rs4633, rs4818, and rs4680 
(val158met)] to explain the mechanism by which the functional outcome of lower enzymatic 
activity is derived. Additional testing of the mRNA degradation rate revealed that HPS 
showed the most stable mRNA, effectively eliminating mRNA instability as a possible 
explanation for the low protein level associated with the HPS haplotype. 
 Attention was focused to the nuances of mRNA secondary structure. Synonymous 
SNPs for the most part are neutral or ‘silent,’ however they still contain the potential to cause 
functional consequences at the level of mRNA. Polymorphic alleles can alter mRNA 
secondary structures (Duan et al., 2003; Shen et al., 1999), which can influence mRNA 
stability, ultimately affecting the rate of mRNA degradation (Puga et al., 2005). Alterations 
in mRNA secondary structure may also affect protein translation efficiency (Mita et al., 
1988; Schmittgen et al., 1994; Shalev et al., 2002). A more stable secondary structure 
requires greater energy to unfold during translation, thereby reducing efficiency. Secondary 
structures may alter protein levels as a direct result of impeded ribosome binding or 
interactions with specific intracellular binding proteins that transport mRNA transcripts to 
the site of translation (Carlini et al., 2001). In COMT mRNA, SNP rs4818 is positioned in at 
the base of a hairpin formation, which is a location known to have an increased potential to 
alter the confirmation (Bonnefoy et al., 2001).  
 mRNA secondary structures of each haplotype were predicted using computer 
programs (RNA Mfold and Afold) that evaluate all possible internal loops and select the 
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structure that minimizes Gibbs free energy (ΔG) (Mathews et al., 1999; Ogurtsov et al., 2006; 
Zuker, 2003). LPS, APS, and HPS haplotypes differed with respect to local mRNA 
secondary structure for both S- and  MB-COMT (Nackley et al., 2006a). Here in the region 
of SNPs rs4818 and rs4680, LPS codes for the shortest, least stable local stem-loop structure 
(ΔG = -20.0 kcal/mol), while HPS codes for the longest, most stable structure (ΔG = -36.7 
kcal/mol) (Fig. 3). 
 LPS, APS, and HPS haplotypes also differed in enzymatic activity for both S- and  
MB-COMT. Compared to the LPS haplotype, the HPS haplotype showed a 25- and 18-fold 
reduction in enzymatic activity for S- and MB-COMT, respectively. This was reflected in the 
marked reductions in S- and MB-COMT protein expression also. The APS haplotype 
exhibited a much less dramatic 2.5- and 3-fold reduction in enzymatic activity for S- and 
MB-COMT, respectively. Protein levels for LPS and APS haplotypes were equivalent. 
 In order to confirm that the mRNA secondary structure contributed to these results, 
site-directed mutagenesis was employed to convert the stable stem-loop structure of HPS to a 
LPS-like conformation. The resulting HPS mutant had identical enzymatic activity and 
protein levels compared to the LPS haplotype, verifying that the local stem-loop structure of 
mRNA was responsible for the decreased enzymatic activity of the HPS haplotype. 
Furthermore, HPS and LPS constructs lacking 5’ and 3’ UTRs necessary for formation of 
stable mRNA secondary structures, had equivalent levels of enzyme activity and protein. 
This is in line with previous conclusions regarding the importance of UTRs in stabilizing 
mRNA secondary structures (Chen et al., 1999).  
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 Thermostability. APS produced protein levels equivalent to those of the LPS 
haplotype. However, the enzymatic activity was reduced by 2.5 to 4.8 fold compared, which 
is within the range that has been previously attributed to the met158 substitution in the earlier-
designated COMTL alleles. The decrease is relatively moderate compared to that of the HPS 
haplotype. The APS haplotype is the only variant of the three that codes for methionine at 
Figure 3. Local mRNA 2º Structures of COMT Haplotypes. Common 
haplotypes of the human COMT gene that are associated with pain sensitivity 
differ with respect to mRNA secondary structure at a local stem-loop structure in 
close proximity to SNPs rs4818 and rs4680. These mRNA folding constructs 
depict the mRNA secondary structures for each of the COMT haplotypes. Arrows 
indicate the position of alternative alleles. The change in Gibb’s free energy is 
lowest for LPS (-20.0 kcal/mole), with higher values for both APS (-28.9 
kcal/mole) and HPS (-36.7 kcal/mole). 
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codon 158. Nackley and colleagues (Nackley et al., 2006a) performed site-directed 
mutagenesis of the HPS haplotype, which resulted in an APS haplotype-like secondary 
structure while maintaining the val158 allele. Enzymatic activity and protein levels were 
equivalent to that of the LPS haplotype. The APS construct lacking 5’ and 3’ UTRs 
necessary for formation of stable mRNA secondary structures, had equivalent levels of 
protein, but maintained a decreased enzymatic activity level compared to the HPS and LPS 
constructs lacking 5’ and 3’ UTRs. It was concluded that the observed reduction in 
enzymatic activity of the APS haplotype was solely attributed to the decreased 
thermostability of the COMT protein brought about the non-synonymous substitution of 
methionine in place of valine at codon 158.
  
PURPOSE OF THE PRESENT STUDY 
 Kimura’s (Kimura, 1985) model of compensatory evolution states that individual 
deleterious mutations may be neutralized by a secondary compensatory mutation. The model 
specifically addresses secondary mutations aimed at maintaining the native confirmation of 
RNA stem-loop structures. The enzymatic activity of COMT haplotypes containing specific 
secondary SNPs  has not been measured. The possibility exists that any secondary SNP may 
be either neutral or complicit in the decreased COMT activity already known to exist  for the 
APS and HPS haplotypes. However, the presence of a  compensatory secondary SNP would 
act to increase COMT activity via partially or completely annulling the effect of the common 
SNPs. 
 There are several examples of beneficial compensatory secondary mutations in 
animals. Gao and Zhang (Gao and Zhang, 2003) reported that rodents possess the mutation 
that is linked to Parkinson’s disease, but that it is rendered phenotypically inert due to an 
accompanying compensatory change. Another study analyzed the mitochondrial sequences of 
nonhuman primates for those containing disease-associated mutations found in humans. 
Some of those sequences related to human pathology were carried by the nonhuman primates 
without consequence due to the simultaneous presence of a secondary compensatory 
mutation (de Magalhaes, 2005). Duan and colleagues (Duan et al., 2003) recently found a 
secondary synonymous mutation within the human dopamine receptor D2 that acts to 
stabilize the mRNA secondary structure in the presence of a known deleterious SNP. The 
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likelihood that a secondary SNP is able to attenuate the deleterious nature of an SNP 
increases with the closer physical proximity of the two SNPs (Stephan and Kirby, 1993). The 
selected minor frequency SNPs studied here have the potential to exert a functional effect 
due in part to their location in the central haploblock. Thus, the purpose of the present study 
was to characterize the potential functional effects of additional SNPs within the central 
haploblock of the S-COMT gene. 
Minor COMT SNPs 
 Four minor SNPs of COMT, which were not previously genotyped for the original 
haplotype construction, were identified. Manual tabulation of expressed sequence tags 
(ESTs), which are incomplete transcribed sequences from a gene containing coding and non-
coding regions, concluded that each SNP was associated with either the APS or HPS 
haplotype. Three SNPs were found to occur with the HPS haplotype: one non-synonymous in 
exon 3 (ala72ser; G/T; rs6267), one synonymous in exon 3 (gln73gln; G/A; rs740602), and 
one synonymous in exon 4 (ala146ala; C/T; 8192488). The minor allele of these three SNPs 
was found in ESTs containing the rs4633 C and rs4818 alleles. One SNP was associated 
exclusively with the APS haplotype in exon 5 (pro158pro; G/A; rs769224), such that the 
minor allele was found in ESTs containing the met158 allele. The four minor SNPs are 
represented in relative position to the common haplotype SNPs in Figure 4. 
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Figure 4. SNPs of COMT Haplotypes. MB-COMT is depicted with coding regions    . The 
relative locations of major and minor SNPs are represented for each haplotype. Common 
SNPs are color-coded in black, while minor SNPs  are color-coded in gray. The associated 
amino acids and codon positions are italiczed. Non-synonomous SNPs and resulting amino 
acid substitutes are bolded. 
 
Potential Functional Effects of Minor SNPs on Existing Haplotypes  
 SNP rs8192488. The synonymous SNP rs8192488 alters the secondary 
structure of COMT mRNA in the proximity of rs4680 (Fig. 5). The resulting conformation, 
as calculated by folding prediction 
software, shows that the large, stable 
stem-loop structure of the HPS 
haplotype is disrupted, so that it 
resembles the secondary structure 
corresponding to the LPS haplotype. 
 SNP rs6267. The non-synonymous SNP rs6267 at codon 72 produces a change 
in amino acid from alanine to serine, which may alter the activity of the COMT enzyme. It is 
 APS 769224 A          T C A  A 
 HPS 6267    A          C T C        G 
 HPS 740602 A          C   A C        G 
 HPS 8192488 A C   C     T G 
 LPS            G          C G G 
rs6269 rs4633 
His62His 
rs4818 
Leu136Leu 
rs4680 
Val158Met 
rs6267 
Ala72Ser 
rs740602 
Gln73Gln  
rs8192488 
Ala146Ala  
rs769224 
Pro199Pro  
Common SNP 
Minor SNP 
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also possible that the ser72 allele is a marker of the HPS haplotype. Alternatively, rs6267 and 
rs4680 could produce a synergistic effect on enzymatic activity. 
Lee (Lee et al., 2005) recently screened 17 known polymorphisms spanning the entire 
length of COMT in Koreans with and without schizophrenia to evaluate for an association 
with the mental disorder. The three minor SNPs associated with the HPS haplotype were 
included in the study. The ser72 allele of the non-synonymous SNP rs6267 was significantly 
associated with both schizophrenia and reduced COMT enzymatic activity. However, effects 
caused by synonymous SNPs rs740602 and rs8192488 could not be determined due to their 
monomorphic presence within the Korean-based population. The study did not seek to 
determine the individual contribution of each SNPs to COMT enzymatic activity. 
 Neither protein level nor enzymatic activity was tested for individual SNPs, however 
COMT activity was associated with SNP rs6267 and rs4680 (Fig. 6). The highest activity 
was obtained from individuals with ala72ala and val158val, which agrees with previous 
studies (Diatchenko et al., 2005; Lotta et al., 1995). COMT activity continued to decrease 
with heterozygous and homozygous diplotypes of the met158 allele. Heterozygotes and 
Figure 6. Lee (Lee et al., 2005) 
reported that red blood cell 
COMT activity is associated 
with SNPs rs6267 (codon 72) 
and rs4680 (codon 158). The 
mean and middle quartiles for  
COMT activities (shown) 
decrease with the presence of 
the of met158 and ser72 alleles 
individually (vertical arrows), 
and decrease significantly more 
when both are present 
(horizontal arrow). P-values are 
given for selected genotypes. 
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homozygotes of the ser72 allele show decreased COMT activity even in the presence of 
val158val, which, as previously discussed, is a marker for both the LPS and HPS haplotypes.  
 SNPs rs740602 and rs769224.The synonymous SNPs rs740602 and 
rs769224 are associated with HPS and APS haplotypes, respectively. Folding analysis did not 
predict a change in the mRNA secondary structure from the parent haplotypes. Either minor 
SNP may ultimately impact enzymatic activity of COMT by enhancing or diminishing 
mRNA stability or altering binding to translocation proteins or ribosomes. 
Summary 
  The individual functional contribution of these four minor SNPs of COMT has not 
been previously characterized. In order to determine positive, neutral or negative 
consequences, parent haplotypes were mutated to create four new mutants, each of which 
contained only one of the minor SNPs. 
 The purpose of this study was to determine the individual effects of specific minor 
SNPs associated with APS (rs769224) and HPS (rs6267, rs740602, rs8192488)  S-COMT 
constructs through quantifying mRNA abundance, protein expression, and enzymatic 
activity. 
 Ultimately, understanding the mechanism by which COMT acts to influence pain 
sensitivity, cognitive functions and disease phenotypes has important clinical implications for 
treatment management and establishing goals for response.
  
MATERIALS AND METHODS 
Confirmation of COMT variants. Previously constructed identical-length cDNA 
clones of the three S-COMT haplotypes (LPS, APS, and HPS) were used in this study. Site-
directed mutagenesis via the Quickchange II XL Site-Directed Mutagenesis Kit (Stratagene, 
LaJolla, CA, USA) was previously employed to create four additional mutants corresponding 
to the SNPs presently studied: APS haplotype (G→A, rs769224); HPS haplotype (G→T, 
rs6267; G→A, rs740602; C→T, 8192488). Plasmid DNA was purified using the EndoFree 
Plasmid Maxi purification kit (Qiagen, Germantown, MD, USA). Once plasmids were 
isolated, DNA sequences were confirmed by double sequencing at the UNC core sequencing 
facility. 
Transient transfection of COMT cDNA clones. A rat adrenal cell 
line (PC-12) was transiently transfected in six-well plates using FuGENE 6 Transfection 
Reagent (Roche) in accordance in manufacture’s recommendations. The amount of plasmid 
was kept at 1 µg/well. The amount of control cDNA plasmid for transfection efficiency 
(pSV-βGalactosidase vector; Promega, Madison, WI, USA and SEAP; Clonetech, Mountain 
View, CA, USA) was kept at 0.1 µg. Transfection with the vector lacking the insert was done 
for each experiment. Cell lysates were collected approximately 48 hours post-transfection. 
Enzymatic assay. After removing the media, cells were washed twice with 0.9% 
saline solution (1 ml/35 mm well) and then covered with deionized water containing 10 mM 
CDTA (300 µl/35 mm well). The wells were freeze/thawed (-80°C/RT) five times and the 
 41 
lysate collected in 1.7 ml tubes. The tubes were centrifuged at 2000 g for 10 min and filtrate 
removed. The enzymatic COMT assay was based on the method described by Masuda’s 
group (Masuda et al., 2002). Purified lysates (8 µl) were incubated with 200 µM Sadenosyl-
L-methionine (SAMe; ICN Chemicals, Aurora OH, USA), 7.5 mM L-norepinephrine (NE; 
Sigma Chemical Co., St. Louis MO, USA) and 2mM MgCl2 in 50 mM phosphate buffered 
saline for 60 min in the final volume of 22 µl. The reaction was terminated using 20 µl of 0.4 
M hydrocholoric acid and 1 µl of 330 mM EDTA. The same reaction in the presence of 15 
mM EDTA was carried out in pararlel for each lysate to bind Mg ions required for COMT 
activity. COMT activity was assessed as measurement of normetanephrine (NMN) by 
Normetanephrine ELISA kit (IBL, Hamburg, Germany) in accordance with manufacture’s 
recommendations using 10 µl of above reaction mixture. COMT activity was determined 
after subtracting the amount of NMN produced by endogenous enzymatic activity 
(transfection with empty vector). The non-specific background was determined in parallel 
assays performed in the presence of EDTA and then subtracted from each reading. COMT 
activity was then normalized for transfection efficiency by measuring the β-galactosidase 
activity for each lysate. βgalactosidase activity was determined using β-galactosidase enzyme 
systems (Promega), according to the supplier protocol. 
Western blot. Purified lysates, normalized for protein content using a BCA assay, 
were run on 12% Novex Tris-Glycine gels (Invitrogen) and transferred to nitrocellulose 
membranes (Whatman, Florham Park, NJ, USA). Blots containing COMT protein were 
blocked with 5% NF milk for 30 min at RT, incubated with COMT polyclonal 1° antibody 
(1:10,000; Chemicon, Temecula, CA, USA) o/n at 4°C, and then incubated with Goat Anti-
Rabbit IgG HRP polyclonal 2° antibody (1:10,000; Chemicon) for 1 hr at RT. Blots were 
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washed with PBST for 10 min at RT, exposed to chemiluminescence reagent (Pierce, 
Milwaukee, WI, USA), and developed. Blots were then stripped using Restore western 
stripping buffer (Pierce) and equal loading of samples verified by β-actin staining. Blots were 
incubated with β-actin polyclonal 1° antibody (1:10,000; Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) for 1 hr at RT followed by Goat Anti-Rabbit IgG HRP polyclonal 2° 
antibody (1:10,000; Chemicon) for 1 hr at RT and chemiluminescent reagent. 
Real-time PCR. Total RNA was isolated using the Trizol reagent (Invitrogen, 
Carlsbad, CA, USA). The isolated RNA was treated with RNase free-DNase I (Promega) and 
reverse transcribed by Superscript III (Invitrogen). The cDNA for COMT and SEAP was 
amplified with DyNAmo-SYBRGreen qPCR kit (MJ Research) using forward and reverse 
PCR primers (TGAACGTGGGCGACAAGAAAGGCAAGAT and 
TGACCTTGTCCTTCACGCCAGCGAAAT, respectively, for COMT and  
GCCGACCACTCCCACGTCTT and CCCGCTCTCGCTCTCGGTAA, respectively, for 
SEAP). Opticon-2 Real Time Fluorescence Detection System. Mastercycler ep (Eppendorf 
AG, Hamburg, Germany) was used for measuring fluorescence. 
Statistical Analyses. For measures of RNA abundance, COMT RNA was 
normalized to SEAP and then analyzed by one-way ANOVA. Protein levels were also 
analyzed by one-way ANOVA followed by Dunnett’s (against LPS) and Bonferroni’s 
(against parent haplotypes) Multiple Comparison post hoc tests. P < 0.05 was considered 
significant for all tests.
  
RESULTS 
COMT RNA Abundance 
 Total RNA levels were calculated from duplicate Real-Time PCR experiments (Fig. 
7). Analysis shows that the RNA abundance was approximately the same for cells transfected 
with clones corresponding to the LPS, APS and HPS haplotypes, as well as the additional 
haplotype constructs containing individual minor SNPs (F6,13 = 1.405, P = 0.3308). 
 
Figure 7. COMT 
RNA abundance. 
No difference in 
total RNA was 
observed for cells 
transfected with the 
parent LPS, APS, 
and HPS constructs 
or APS/HPS minor 
SNP constructs.  
 
 
  
 Specifically, the inclusion of  the rs769224 minor allele in the APS haplotype did not 
result in significant change of total RNA relative to the APS haplotype. Similarly, in 
comparison to the HPS haplotype, the presence of the individual minor alleles at rs8192488, 
rs740602, and rs6267 did not significantly affect the RNA level. 
 44 
COMT Protein Expression 
COMT protein levels obtained from duplicate experiments were normalized to corresponding 
β-actin levels and statistically analyzed (Fig. 8). Similar to previous studies, the HPS 
haplotype exhibited reduced protein expression levels relative to LPS haplotype (F6,13 = 
6.133, P < 0.02), while the APS haplotype exhibited protein levels that did not differ from 
those corresponding to the LPS haplotype. However, no differences in protein expression 
were observed between the APS and APS + rs769224 A constructs or between the HPS and 
HPS + rs8192488, HPS + rs740602, or HPS + rs6267 constructs.  
 
Figure 8.  COMT 
protein level. 
Western Blot data 
from duplicate 
experiments is shown 
(top) and averaged 
(bottom). The HPS 
haplotype and HPS 
mutants 819 
(rs8192488), 740 
(rs740602) and 6267 
(rs6267) exhibited 
the lowest COMT 
protein expression 
and were significant-
ly different from the 
LPS haplotype (*). 
All HPS mutants 
expressed an 
equivalent protein 
level as compared to 
the HPS haplotype. 
LPS, APS, and APS 
mutant 769 
(rs769224) showed 
equivalent protein 
levels. 
Data expressed as 
Mean ± SEM.  
* 
* 
* * 
 45 
COMT Enzymatic Activity 
 ELISA results showed that COMT enzymatic activity varied among COMT 
haplotypes and haplotype mutants (Fig. 9). Compared to the LPS haplotype, the APS and 
HPS haplotypes exhibited a 5- and 18-fold reduction in activity, respectively. The APS + 
rs769224 A yielded a similar decrease in activity as the APS haplotype. Similarly, the 
magnitude of reduction for HPS + rs8192488 T, HPS + rs740602 A, and HPS + rs6267 T 
was comparable to that associated with the HPS haplotype. 
 
Figure 9. COMT 
enzymatic activity. 
Both APS and HPS 
haplotypes exhibited a 
reduction in enzymatic 
activity as compared to 
the LPS haplotype, 
approximately 5- and 
18-fold respectively. 
No differences were 
observed between the 
APS and APS + 
rs769224 A or 
between the HPS and 
HPS + rs8192488 T, 
HPS + rs740602 A, or 
HPS +  rs6267 T 
constucts. 
 
  
 
 
  
DISCUSSION 
 The objective of this study was to evaluate the functional effect of select lower-
frequency, naturally-occurring SNPs within the central haploblock of the human COMT gene 
locus on protein expression and enzymatic activity of the previously characterized APS and 
HPS pain-related COMT haplotypes. 
 The data for total RNA abundance, protein expression, and enzymatic activity for the 
pain-related haplotypes agreed with previous studies (Diatchenko et al., 2005; Nackley et al., 
2006a). As in previous studies, total RNA abundance did not differ between any of the APS 
or HPS parent or minor SNP constructs. For the APS haplotype, a less dramatic, but still 
significant, decrease in enzymatic activity was associated with near equivalent levels of total 
RNA and protein as compared to the LPS haplotype. A similar result was found for the APS 
mutant (rs769224). Statistically, there was no difference for any of the measures between the  
haplotype constructs containing the minor alleles of the minor SNPs and their respective 
parent haplotype. 
 A disruption of the local stable stem-loop structure of the HPS mRNA was predicted 
in the presence of the minor allele for SNP rs8192488. The rs8192488 effect on the 
conformation of HPS appears to be substantial, however the resulting Gibb’s free energy 
value was not calculated. Thus,  it is unknown how similar to the LPS haplotype 
conformation the resulting stem-loop structure really is. Results suggest that rs8192488 does 
not have any functional consequence on the HPS haplotype. 
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 Evidence of functionality, both beneficial and deleterious, exist for synonymous 
SNPs (Duan et al., 2003). The results for the two minor synonymous SNPs assessed in this 
study suggest that rs769224 and rs740602 have a neutral effect on RNA abundance, protein 
expression, and enzymatic activity for the APS and HPS haplotypes, respectively. 
 As for the nonsynonymous SNP rs6267, no difference was detected when compared 
to the HPS haplotype for any of the measures. The individual contribution to phenotype 
measures such as pain sensitivity, however, cannot be determined from this study. Still, when 
comparing these results with those of Lee and colleagues (Lee et al., 2005), an interesting 
relationship is discovered. Lee reported that human subjects displaying both the highest and 
lowest red blood cell COMT activity were homozygous for the val158 allele, which 
corresponds to SNP rs4680, one of the four common SNPs in the parent haplotypes. LPS and 
HPS haplotypes have the same amino acid sequence, and therefore both code for the val158 
allele. The SNP rs6267 minor allele, which codes for ser72, exclusively occurs within the 
HPS haplotype as found from EST data. This is highly suggestive that rs6267 is a marker of 
the HPS haplotype (Fig. 10). 
  
Figure 10. rs6267 as a marker for HPS. 
LPS and HPS code for the val158 allele, 
which was associated with both the highest 
(red box) and lowest (blue box) red blood 
cell COMT activity. The minor allele of SNP 
rs6267 codes for ser72, which occurs 
exclusively in the HPS haplotype, and is 
associated with lower activity. These data 
suggest that rs6267 is a likely marker for the 
HPS haplotype. 
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 The results of the present study support that the effect of the val158met allele is not 
compensated for by the presence of the SNP rs769224 in the APS haplotype. Additionally, 
these results further support that the common SNPs of HPS have a profound effect on protein 
level and enzymatic activity, and the inclusion of additional minor SNPs do not affect the 
functional activity of the HPS haplotype.
  
CONCLUSION  
 From a subset of less-frequently occurring SNPs, a group of four minor SNPs 
exclusively present in either the APS or HPS haplotype were selected for this study. Data 
were in agreement with previous studies, showing that the COMT pain-related haplotypes did 
not vary significantly in mRNA abundance, but that the APS and HPS haplotypes exhibited a 
decrease in enzymatic activity of five- and 18-fold, respectively. Furthermore, the HPS 
haplotype showed a significant decrease in protein level compared to the LPS haplotype. 
 The presence of individual minor SNPs within their parent haplotype did not 
significantly alter the level of mRNA, protein or activity. While SNPs may impart a 
beneficial or deleterious effect on protein functionality, in the present study, the selected 
minor SNPs were shown to have a neutral effect on COMT enzymatic activity within their 
exclusive parent haplotypes. None of the minor SNPs tested compensated for the APS- and 
HPS-dependent reductions in enzymatic activity. However, an interesting finding is that the 
non-synonymous SNPs rs6267 is a potential marker for the HPS haplotype. 
  
SUMMARY 
 The leading question in this study was to determine whether naturally occurring SNPs 
present within the central haplobock of the human COMT gene locus would impact the 
protein level and/or enzymatic activity of the pain-related APS and HPS haplotypes 
previously described (Diatchenko et al., 2005). A line of evidence was assembled to justify 
the rationale that the inclusion of a secondary SNP may effect a functional consequence in 
the presence of an otherwise deleterious SNP (de Magalhaes, 2005; Duan et al., 2003; 
Kimura, 1985; Stephan and Kirby, 1993). Herein lied the possibility of identifying a 
beneficial compensatory effect relating to a minor SNP within COMT. 
 SNPs within coding or non-coding regions have the potential to effect functional 
consequences. Site-directed mutagenesis was used to construct single point mutations: one in 
the APS construct (G/A; rs769224) and three in the HPS construct (C/T; rs8192488, G/A; 
rs740602, or G/T; rs6267). Rat adrenal (PC-12) cells were transiently transfected with each 
of the four constructs. COMT mRNA abundance, protein expression, and enzymatic activity 
were measured and analyzed. 
 One-way ANOVA and, when appropriate, subsequent post hoc tests were completed 
for total RNA and protein expression. Results were compared to data of previous studies 
using the same parent haplotypes. The significance level was set at 0.05 for all tests. 
 The results for the parent haplotypes were in complete agreement with previous 
studies. No difference existed in total RNA, protein expression, or enzymatic activity when 
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the minor alleles of SNPs rs769224, rs8192488, rs740602, or rs6267 were individually 
compared to their respective parent haplotypes. Therefore, the minor SNPs studied here have 
a neutral effect on the pain-related APS and HPS haplotypes. 
 In addition, comparing the present results with those from Lee (Lee et al., 2005) 
suggest that SNP rs6267 is likely to be a marker of the HPS haplotype. 
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